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Abstract
Nonsteroidal anti-inflammatory drugs are among the most commonly used prescription and over-the-counter medications,
but they often produce significant gastrointestinal ulceration and bleeding, particularly in elderly patients and patients with
certain co-morbidities. Novel anti-inflammatory drugs are seldom tested in animal models that mimic the high risk human
users, leading to an underestimate of the true toxicity of the drugs. In the present study we examined the effects of two
novel NSAIDs and two commonly used NSAIDs in models in which mucosal defence was expected to be impaired.
Naproxen, celecoxib, ATB-346 (a hydrogen sulfide- and naproxen-releasing compound) and NCX 429 (a nitric oxide- and
naproxen-releasing compound) were evaluated in healthy, arthritic, obese, and hypertensive rats and in rats of advanced
age (19 months) and rats co-administered low-dose aspirin and/or omeprazole. In all models except hypertension, greater
gastric and/or intestinal damage was observed when naproxen was administered in these models than in healthy rats.
Celecoxib-induced damage was significantly increased when co-administered with low-dose aspirin and/or omeprazole. In
contrast, ATB-346 and NCX 429, when tested at doses that were as effective as naproxen and celecoxib in reducing
inflammation and inhibiting cyclooxygenase activity, did not produce significant gastric or intestinal damage in any of the
models. These results demonstrate that animal models of human co-morbidities display the same increased susceptibility to
NSAID-induced gastrointestinal damage as observed in humans. Moreover, two novel NSAIDs that release mediators of
mucosal defence (hydrogen sulfide and nitric oxide) do not induce significant gastrointestinal damage in these models of
impaired mucosal defence.
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Introduction
The ability of nonsteroidal anti-inflammatory drugs (NSAIDs) to
cause significant ulceration and bleeding in the stomach and
duodenum is well recognized [1]. Less appreciated, until the recent
advent of video capsule endoscopy, is the full extent of detrimental
effects these drugs exert on the intestinal tract distal to the ligament
of Treitz [2], which appear to be produced via mechanisms distinct
from those responsible for gastro-duodenal injury [1,3]. Therapies
aimed at preventing NSAID-induced gastrointestinal (GI) injury
havelargelyfocusedongastroduodenaldamage.Themostcommon
approach used clinically to minimize gastroduodenal injury is to co-
administeraprotonpumpinhibitor(PPI)withtheNSAID.Thishas
beenshownto significantlyreduce theincidenceofgastro-duodenal
damage [4], but recent animal studies suggest that suppression of
acid secretion can lead to exacerbation of NSAID-induced small
intestinal injury and bleeding [5]. There are several clinical studies
that report high levels of intestinal damage in healthy volunteers
taking NSAIDs plus a PPI [6–9], and one study showing significant
elevation of a marker of intestinal inflammation (calprotectin) in
patients taking PPIs [10].
Selective inhibitors of cyclooxygenase (COX) -2 entered the
marketplace at the turn of the last century with great promise for
GI safety. This promise has largely been unfulfilled [11]. However,
even the small upper GI benefit gained through use of a selective
COX-2 inhibitor versus a non-selective COX inhibitor is lost
when low-dose aspirin is co-administered [12,13]. This co-therapy
is aimed at reducing the incidence of cardiovascular events
associated with the use of selective and most non-selective NSAIDs
[14]. Low-dose aspirin, alone, can also cause significant small
intestinal injury [15]. Studies to evaluate the effects on the GI tract
of the combined use of an NSAID, a PPI and low-dose aspirin,
which is now a common combination in clinical practice, have not
been reported.
One of the problems encountered in attempts to develop GI-
sparing NSAIDs is that preclinical studies have largely focused on
the stomach (ignoring the small intestine) and are usually
performed using healthy animals. The latter may give false
security about the safety of the drug, which in humans will be used
by individuals with significant co-morbidities and compromised
mucosal defence. It is therefore important to evaluate the safety
and efficacy of novel NSAIDs in models that more closely
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35196resemble the patients who will be the major users of these drugs.
NSAID-induced gastroduodenal injury has been reported to be
elevated in elderly patients, and in patients with co-morbidities
such as obesity, hypertension and rheumatoid arthritis [16–18].
Novel NSAIDs should also be evaluated in combination with the
drugs that are often co-prescribed with NSAIDs (e.g., proton
pump inhibitors and low-dose aspirin), given that these drugs may
exacerbate NSAID-induced GI damage. This approach will make
the data more predictive of the human response, therefore
providing more insight on the potential GI safety of drugs
intended for use as treatments of inflammatory conditions.
In the present study, we examined the effects of a number of
NSAIDs in models that attempt to mimic relevant clinical
scenarios of NSAID use. Two of the most commonly used
NSAIDs (naproxen and celecoxib) were compared to each other
and to two novel, putative GI-sparing NSAIDs (both chemically
related to naproxen; one nitric oxide-releasing and the other
hydrogen sulfide-releasing). Both nitric oxide and hydrogen sulfide
have been shown to exert protective effects in the GI tract [1], and
NSAID compounds that release one of these gaseous mediators
produce significantly less GI damage than their respective parent
drugs in healthy animals [19,20].
In addition to examining the GI safety of these compounds
when administered together with low-dose aspirin and/or a PPI,
we evaluated them in models in which mucosal defence may be
compromised (i.e., obese rats, arthritic rats, hypertensive rats and
aged rats). In all studies we compared the test drugs at doses that
produced comparable anti-inflammatory effects in rats with
adjuvant arthritis.
Methods
Animals
Male, Wistar rats weighing 180–220 g and male, Zucker rats
(both lean and obese, weighing ,360 and ,560 g, respectively),
spontaneously hypertensive rats (SHR) and normotensive rats
(Wistar-Kyoto; WKR) (180–220 g) were obtained from Charles
Rivers (Montreal, QC, Canada). 19-month old, male, Sprague
Dawley rats (mean weight of 525 6 30 g) were obtained from
Harlan Laboratories (Indianapolis, IN, USA). All rats were housed
in the Central Animal Facility at McMaster University. The rats
were fed standard chow and water ad libitum, and were housed in
pairs in a room with controlled temperature (22 6 1uC), humidity
(65–70%) and light cycle (12 h light/12 h dark). All experimental
procedures described herein were approved by the Animal Care
Committee of the Faculty of Health Sciences at McMaster
University. The studies were carried out in accordance with the
guidelines of the Canadian Council of Animal Care. The health of
the animals was assessed at least twice-daily, and any animals in
distress or having lost .15% of their original body weight were
euthanized by an overdose of sodium pentobarbital.
Test Drugs
Naproxen and ATB-346 (2-(6-methoxy-napthalen-2-yl)-propio-
nic acid 4-thiocarbamoyl-phenyl ester) were tested in all models,
and in some models the effects of celecoxib and NCX 429 [(S)-6-
(nitrooxy)hexyl 2-(6-methoxynaphthalen-2-yl)propanoate] were
also examined. Naproxen and celecoxib were administered at a
dose of 10 mg/kg. This dose was selected because it produced
significant and comparable activity in reducing paw swelling in
rats with adjuvant arthritis (see below) [21]. In all studies described
below, ATB-346 and NCX 429 were given at doses equimolar to
the dose of naproxen. All test drugs were suspended in
dimethylsulfoxide/1% carboxymethylcellulose; 5:95 ratio).
Adjuvant Arthritis Model
Polyarthritis was induced in Wistar rats via an injection into the
base of the tail of 100 mL of Freund’s Complete Adjuvant
containing 0.75 mg of heat-killed Mycobacterium butirricum [21]. The
volume of the hindpaws of each rat was blindly measured using a
hydroplethysmometer (Ugo Basile, Comerio, Italy) prior to the
injection of the adjuvant, and on days 7, 10, 14 and 18 after
adjuvant administration. Groups of rats (n=8 each) were treated
twice-daily beginning on day 7 with celecoxib (10 mg/kg),
naproxen (10 mg/kg), or equimolar doses of ATB-346
(14.5 mg/kg) or NCX 429 (15 mg/kg). Two control groups (one
with adjuvant arthritis and one naive) were treated with an equal
volume of vehicle. At the end of the study the stomach and small
intestine were excised and blindly evaluated for hemorrhagic
damage, as described below.
NSAID-Induced Gastroenteropathy
Unless otherwise noted, studies of NSAID-induced gastroenter-
opathy were performed in healthy (2-month old) Wistar rats. Rats
were given one of the test drugs or vehicle orally, twice each day
for 4.5 days (9 administrations in total). Three hours after the final
administration of drug or vehicle, the rats were anesthetized with
sodium pentobarbital and blood was drawn from the aorta for
ELISA measurement of whole blood thromboxane B2 (TXB2)-
synthesis, as an index of systemic COX-1 activity [22]. The
stomach and small intestine were then blindly evaluated for
hemorrhagic damage. This involved measuring the lengths, in
mm, of all hemorrhagic lesions. Separate gastric and intestinal
damage scores were then calculated by summing the lengths of all
lesions for each rat [5]. After scoring, samples of the jejunum and
of the corpus region of the stomach were collected for the
measurement of prostaglandin (PG)E2 synthesis, as described
previously [23]. Finally, specimens of gastric and jejunal tissues
were fixed and processed for histological examination (H&E
staining).
Polypharmacy Model
Groups of Wistar rats (n.6/group) were treated for a total of 9
days with one or more drugs. The rats received omeprazole
(10 mg/kg) or vehicle twice-daily (ip) throughout the 9 days.
Beginning on day 2, the rats received vehicle or low-dose aspirin
(10 mg/kg) orally once daily. Beginning on day 5, the rats received
an NSAID or vehicle orally twice-daily. The rats were euthanized
3 hours after the final administration of the NSAID or vehicle for
blind evaluation of the extent of damage to the stomach and small
intestine, as described above. Samples were taken for measure-
ment of prostaglandin and thromboxane synthesis, as described
above. Previously we demonstrated that the dose of omeprazole
used in this study produced a 99% inhibition of gastric acid
secretion by the 5
th day of administration (when NSAID treatment
was initiated) [5]. Daily administration of aspirin at 10 mg/kg
produced 95% inhibition of whole blood thromboxane synthesis
by the 3
rd day of administration (when NSAID treatment was
initiated) [5].
Advancing Age Model
Studies were performed, as described above, using rats that
were 19 months of age (n=6/group).
Obesity Model
Male, Zucker rats of the fa/fa phenotype spontaneously develop
to an obese state, whereas their Fa/fa littermates exhibit normal
weight gain [24]. Obese and lean Zucker rats (n=6/group) were
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(10 mg/kg), ATB-346 (14.5 mg/kg), or vehicle (1% CMC,
DMSO (95:5)) for a total of 4.5 days. 3 hours after the final dose,
the rats were euthanized, the stomach and small intestine were
blindly evaluated for damage and sample collection was conducted
as described above (NSAID-Induced Gastroenteropathy). In order to
determine if any of the rats were diabetic, as has been reported
[25], blood glucose levels were determined prior to and after
NSAID dosing using a Freestyle Freedom Lite unit (Abbott
Diabetes Care, Saint-Laurent, QC, Canada).
Hypertension Model
To confirm that the spontaneously hypertensive rats were
indeed hypertensive, blood pressure was measured in SHR and
normotensive WKR using a CODA Non-Invasive (tail-cuff) Blood
Pressure System (Kent Scientific Corporation, Torrington, CT,
USA). In order to minimize stress-induced alterations in blood
pressure, each rat underwent a daily 15-minute training session in
the device for 3 days prior to blood pressure determination. The
rats were acclimated for 10 min in advance of blood pressure
readings and placed on a heating blanket (36uC) to promote
thermo-regulation and maintain tail blood flow. Blood pressure
measurements were performed two days prior to beginning
NSAID administration. The rats received naproxen (10 mg/kg),
an equimolar dose of ATB-346 (14.5 mg/kg) or vehicle orally
twice-daily for 4.5 days. 3 hours after the final administration of
the test drugs the rats were euthanized and the extent of gastric
and small intestinal damage was blindly evaluated, as described
above. Samples were taken for measurement of gastric PGE2 and
whole blood TXB2 synthesis, as described above.
Pharmacokinetics
Rats were treated with a single, oral dose of naproxen (10 mg/
kg), ATB-346 (14.5 mg/kg) or NCX 429 (15 mg/kg). Subgroups
(n=4 each) of rats were anesthetized with sodium pentobarbital
4 h later. The bile duct was cannulated and bile was collected for
30 minutes [26], after which a blood sample was drawn from the
descending aorta. 50 mL of bile or serum samples were de-
proteinated by adding three volume of acetonitrile and 10 mLo f
dimethylsulfoxide. Samples were then centrifuged for 10 min at
4uC (32006g) and the supernatants were transferred to a 96-well
plate for analysis using a LC-MS/MS system for quantification of
naproxen [5]. A calibration curve of naproxen in both serum and
bile was prepared in the concentration range 0.1–300 mM.
Materials
ATB-346 (2-(6-methoxy-napthalen-2-yl)-propionic acid 4-thio-
carbamoyl-phenyl ester) was provided by Antibe Therapeutics Inc.
(Toronto, ON, Canada) and NCX 429 [(S)-6-(nitrooxy)hexyl 2-(6-
methoxynaphthalen-2-yl)propanoate] was provided by NicOx
S.A. (Sophia Antipolis, France). Celecoxib was obtained from
American Custom Chemical Corp. (San Diego, CA, USA).
Sodium naproxen and streptozotocin were purchased from
Sigma-Aldrich (St. Louis, MO, USA). ELISA kits for measuring
TXB2and PGE2were obtained from Cayman Chemicals (Ann
Arbor, MI, USA). Freund’s Complete Adjuvant and Mycobacterium
butirricum were purchased from Difco Laboratories (Detroit, MI,
USA).
Statistical Analyses
Data are expressed as the mean 6 SEM. Comparisons among
groups of data were performed by one-way analysis of variance
followed by a post hoc test (Dunnett’s Multiple Comparison Test
for parametric data and Mann Whitney Test for non-parametric
data). An associated probability (p value) of less than 5% was
considered significant.
Results
Efficacy Studies
Rats with adjuvant arthritis were treated from day 7 to day 21,
twice-daily, with the test drugs or vehicle. Fig. 1A illustrates that
each of the drugs, at the doses tested, produced comparable
reductions in paw edema, reducing paw volumes to levels not
different from those of healthy rats. Consistent with the
comparable anti-inflammatory effects, the test drugs produced
comparable suppression of gastric prostaglandin E2 synthesis
(Fig. 1B) and systemic COX-1 activity (whole blood thromboxane
synthesis) (Fig. 1C). Despite this, the extent of gastric and small
intestinal damage differed among the treatment groups. Naproxen
caused significant gastric and intestinal damage, while the levels of
damage were negligible with celecoxib, ATB-346 and NCX 429
(not significantly different from that in vehicle-treated rats) (Fig. 1D
and 1E).
GI Damage in Healthy, Young Rats
In healthy, 2-month old Wistar rats, administration of naproxen
twice-daily for 4.5 days results in very little detectable damage in
the stomach or small intestine. The mean damage scores were 1.3
6 0.5 for the stomach and 1.0 6 0.5 for the small intestine (n= 8;
see Fig. 2 for intestinal damage). Similarly, celecoxib, ATB-346,
NCX 429 and low-dose aspirin produced negligible gastric and
small intestinal damage in healthy young rats.
Polypharmacy Model
The test drugs were also assessed for their ability to induce
gastrointestinal damage in circumstances mimicking the clinical
scenario in which patients receive co-treatment with a ‘gastro-
protective’ drug and/or low-dose aspirin (to provide ‘cardio-
protection’). Gastric damage remained low in rats co-treated with
one of the NSAIDs and omeprazole and/or low-dose aspirin
(mean damage scores of ,3). However, when naproxen or
celecoxib were administered together with low-dose aspirin, the
extent of hemorrhagic injury in the small intestine increased
markedly (p,0.05) over that observed with either drug alone
(Fig. 2). Similarly, co-administration of the proton pump inhibitor
(omeprazole) with naproxen or celecoxib resulted in a dramatic
increase in the extent of small intestinal damage. The combination
of either naproxen or celecoxib with both low-dose aspirin and
omeprazole resulted in the highest intestinal damage scores (Fig. 2).
In sharp contrast to the effects observed with naproxen and
celecoxib, administration of ATB-346 or NCX 429 together with
low-dose aspirin and/or omeprazole did not result in significant
intestinal damage (Fig. 2).
Studies in Aged Rats
In rats that were 19 months of age, twice-daily administration of
naproxen for 4.5 days resulted in the development of extensive
gastric damage that consisted of both of erosions and penetrating
ulcers (Fig. 3). Histological evaluation confirmed that damage in
the older rats penetrated through the muscularis mucosae into the
submucosa. In contrast to the studies in younger rats, the older rats
did not develop significant intestinal damage when treated with
naproxen. Older rats treated with celecoxib, ATB-346 or NCX
429 did not develop significant gastric or intestinal damage.
However, ATB-346 and NCX 429 suppressed (.95%) gastric
GI-Sparing NSAIDs and Compromised Mucosal Defence
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as naproxen.
Studies in Obese Rats
Treatment of lean Zucker rats (mean weight of ,360 g) with
naproxen twice-daily for 4.5 days resulted in a small amount of
damage in the stomach and intestine (Fig. 4), similar to that seen in
Wistar rats. Obese Zucker rats (mean weight of ,560 g) did not
exhibit gastric damage, but they developed much more severe
small intestinal damage when treated with naproxen (p,0.01
versus the lean counterparts). ATB-346 did not produce detectable
gastric or intestinal damage in either lean or obese Zucker rats.
Whole blood thromboxane synthesis was markedly higher in the
obese rats than in the lean littermates (632 6 110 vs 105 6 36 ng/
mL, respectively; p,0.01). However, in both groups of rats
naproxen and ATB-346 caused near-complete suppression
(.95%) of whole blood thromboxane synthesis and gastric PGE2
synthesis.
Figure 1. Effects of NSAIDs in rats with adjuvant arthritis.
Despite comparable suppression of paw swelling (panel A), gastric
prostaglandin synthesis (panel B) and whole blood thromboxane
synthesis (panel C), ATB-346 and NCX 429 did not cause significant
gastric (panel D) or intestinal (panel E) damage. Celecoxib also did not
cause significant GI damage. *p,0.05, **p,0.01 versus the naproxen-
treated group. n=8 per group.
doi:10.1371/journal.pone.0035196.g001
Figure 2. Co-administration of naproxen or celecoxib with
omeprazole and/or low-dose aspirin results in marked exacer-
bation of small intestinal damage. In contrast, rats given a
naproxen derivative (ATB-346 or NCX 429) did not develop significant
intestinal injury when given alone or in combination with omeprazole,
low-dose aspirin, or both. *p,0.05, **p,0.01 versus the corresponding
group treated with NSAID alone (n$6 per group). Aspirin and
omeprazole, alone or given together, did not elicit significant intestinal
damage.
doi:10.1371/journal.pone.0035196.g002
Figure 3. Older (19 months of age) rats develop extensive
gastric damage when given naproxen, but not when given
equimolar doses of a hydrogen sulfide-releasing naproxen
derivative (ATB-346) or a nitric oxide-releasing naproxen
derivative (NCX 429). ***p,0.001 versus the vehicle-treated group.
n= 6 rats per group.
doi:10.1371/journal.pone.0035196.g003
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glucose levels were all within the normal range (5.5 6 1.1 mmol/L
in lean vs. 5.5 6 1.2 mmol/L in obese).
Studies in Hypertensive Rats
SHR rats had markedly elevated systemic blood pressure as
compared to the normotensive (Wistar-Kyoto) rats (Fig. 5a). When
treated with naproxen or ATB-346 twice-daily for 4.5 days, no
significant gastric damage was observed in either group of rats
(Fig. 5b). Intestinal damage was not observed in either group of
rats with either test drug. The test drugs produced comparable
suppression of gastric PGE2 and whole blood thromboxane
synthesis in both hypertensive and normotensive rats (Fig. 5c
and 5d). However, the control hypertensive rats did exhibit
marked elevations of whole blood thromboxane synthesis (,3.5-
fold), as has been reported previously [27].
Pharmacokinetics
Four hours after a single dose of naproxen, serum levels of
naproxen averaged 98 6 5 mM. Naproxen levels 4 h after a single
dose of ATB-346 were 53 6 mM (not significantly different), while
4 h after a single dose of NCX 429, serum naproxen levels were
only 29 6 8 mM( p ,0.05 versus the naproxen-treated group).
When bile levels of naproxen were measured 4 h after
administration of the test drugs, some dramatic differences were
apparent. In the naproxen-treated group, bile naproxen levels
averaged 1.5 6 0.3 mM, while bile naproxen levels in the rats
treated with ATB-346 or NCX 429 were significantly (p,0.05)
lower, at 0.5 6 0.1 and 0.2 6 0.1 mM, respectively.
Similar differences in serum and bile levels of naproxen were
observed in rats treated twice-daily for 2 days with naproxen,
ATB-346 or NCX 429 (Fig. 6).
The mass spectrum analysis of bile samples from rats treated
once or four times with the test drugs also detected a naproxen
glucuronide, which was more evident in the samples from
naproxen-treated rats than in samples from rats treated with
ATB-346 or NCX 429. Thus, after a single dose of the test drugs,
the ratio of the naproxen glucuronide in samples from naproxen-,
ATB-346- and NCX 429-treated rats was 22:10:3. After four doses
of the test drugs, the ratio changed to 32:9:7.
Discussion
NSAID-induced gastroenteropathy is a significant limitation to
the use of this class of drugs, which is a mainstream therapy for
osteoarthritis and other chronic conditions characterized by
Figure 4. Increased naproxen-induced small intestinal damage
in obese versus lean rats. Neither lean nor obese rats developed
intestinal damage when given ATB-346. **p,0.01 versus the corre-
sponding vehicle- and ATB-346-treated rats. n=6 rats per group.
doi:10.1371/journal.pone.0035196.g004
Figure 5. Severity of gastric damage induced by naproxen is
similar in spontaneously hypertensive (SHR) and normotensive
(WKY) rats. ATB-346 suppressed gastric prostaglandin (PG)E2 synthesis
and whole blood thromboxane (TXB2) synthesis as effectively as
naproxen, but did not elicit gastric damage. ***p,0.001 versus the
corresponding vehicle-treated group (n=6 per group).
doi:10.1371/journal.pone.0035196.g005
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more frequently in the elderly, in patients taking anti-platelet/anti-
coagulants (including aspirin), and in patients with co-morbidities
such as rheumatoid arthritis, obesity, heart failure and hyperten-
sion [16–18]. Evaluation of tolerability and safety of NSAIDs in
animal models that more closely mimic these clinical scenarios will
likely provide more relevant predictive data than studies in healthy
animals. In the present study, we compared the GI damage of
several NSAIDs in rat models of arthritis, polypharmacy, obesity,
advancing age and hypertension. Our results demonstrated that in
most of these models (hypertension being the exception), the
severity of NSAID-induced gastric and/or intestinal damage was
markedly elevated as compared to that in healthy rats. In contrast
to naproxen (and in some studies celecoxib), hydrogen sulfide- and
nitric oxide-releasing naproxen compounds (ATB-346 and NCX
429, respectively) elicited negligible GI damage, despite still
inhibiting the key target enzymes for their anti-inflammatory and
GI-damaging effects (COX-1 and COX-2). The novel NSAIDs
also exhibited comparable anti-inflammatory activity to naproxen
and celecoxib in rats with adjuvant arthritis.
Studies in co-morbidity models may provide insights on the
pathogenesis of NSAID-gastropathy and –enteropathy. For
example, it was interesting that the older rats (19-month old),
unlike younger rats (2-month old), developed severe gastric but not
intestinal damage. As well as the damage being more extensive in
the stomach of older rats, it was also more severe in terms of depth
of injury (i.e., penetrating ulcers rather than superficial erosions).
The reasons for the propensity of gastric damage (rather than
intestinal) in the older rats are unclear, but could be attributable to
the reported deficiencies in gastric mucosal defence that occur
with age. For example, impaired gastric production of nitric oxide,
a key mediator of mucosal defence [28], has been reported in older
rats [29], as has reduced gastric prostaglandin synthesis [30].
Arthritic rats exhibited increased susceptibility to gastric and
intestinal damage as compared to healthy controls. One of the
factors that might contribute to this increase in injury is the
enhanced NSAID-induced leukocyte adherence to the vascular
endothelium that has been observed in arthritic rats [31].
Leukocyte adherence to the vascular endothelium is a critical
early event in pathogenesis of NSAID-gastropathy [32,33], and
also plays an important role in the development of NSAID-
induced injury in the small intestine [34].
Bacteria play a role in the initiation and chronicity of ulcers in
the intestine and the stomach [35–37]. Indeed, NSAID-induced
small intestinal damage does not develop in germ-free animals
[36]. Obese Zucker rats have a distinct microbiome from their
lean counterparts, with a significant reduction of Bifidobacteria [38],
but we can only speculate, at this point in time, that these
differences contribute to the increased susceptibility of obese rats
to NSAID-induced enteropathy.
We previously reported that suppression of gastric acid secretion
in rats led to a dramatic shift in the microbiota (notably a
significant decrease in Bifidobacteria spp.) and a marked increase in
the susceptibility to NSAID-induced small intestinal damage [5].
The increase in susceptibility to damage could be transferred via
the microbiota. In the present study, we extended those finding
with the demonstration that administration of low-dose aspirin
significantly increases the severity of NSAID-induced small
intestinal damage, and found that even greater damage was
observed when both omeprazole and low-dose aspirin were co-
administered with the NSAID. This is a very common
combination of drugs in humans. Proton pump inhibitors are
given to reduce the incidence of NSAID-induced gastroduodenal
damage, while low-dose aspirin is given to reduce the incidence of
NSAID-associated cardiovascular events [12]. No published
human studies have examined the effects of co-administration of
an NSAID, low-dose aspirin and a proton pump inhibitor on the
small intestine. However, a high level of intestinal damage was
observed in several video capsule endoscopy studies of healthy,
young volunteers given an NSAID plus a PPI over a short period
of time [6–9], and detrimental effects of low-dose aspirin on the
small intestine are well documented [15]. Given the results of the
present study, and how widespread the polypharmacy approach is
practiced, clinical studies of the GI impact of the combination of
an NSAID, low-dose aspirin and a PPI are warranted.
NO and H2S have well characterized protective [1,28,39,40]
and ulcer-healing [41–43] effects in the gastrointestinal tract, and
both have been exploited in the design of GI-sparing anti-
inflammatory drugs [44,45]. In the present study, ATB-346 and
NCX 429 spared the stomach and small intestine of damage,
regardless of the model in which they were tested, and despite the
fact that they markedly suppressed mucosal prostaglandin
Figure 6. Serum and biliary levels of naproxen are significantly
reduced in rats given a naproxen derivative (ATB-346 or NCX
429) as compared to the levels observed in rats given an
equimolar dose of naproxen itself. The test drugs were adminis-
tered twice-daily for 2 days. *p,0.05, **p,0001 versus the naproxen-
treated group. n=4 per group.
doi:10.1371/journal.pone.0035196.g006
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effects are likely due largely to the mucosal-protective effects of the
gaseous mediator released from these drugs (H2S from ATB-346
and NO from NCX 429), and to the ability of these mediators to
inhibit leukocyte adherence [1,46]. However, the pharmacokinetic
studies suggest another mechanism for the safety of ATB-346 and
NCX 429, particularly in terms of tolerability in the small
intestine. The enterohepatic circulation of NSAIDs is critical to
their ability to induce small intestinal injury [26,37]. We observed
that there were very low levels of naproxen in the bile following
administration of ATB-346 or NCX 429, relative to biliary
naproxen concentrations following administration of naproxen
itself. Unlike naproxen, ATB-346 and NCX 429 do not have free
carboxylic acid residues, so would likely have greatly reduced
topical irritant properties than naproxen.
In summary, animal models of obesity, advancing age, arthritis
and polypharmacy exhibit a significant increase in susceptibility to
NSAID-induced GI damage. These models may be more
predictive of the properties of NSAIDs in the subset of humans
that develop the most adverse GI events when taking these drugs.
H2S- and NO-releasing derivatives of naproxen were found to be
very well tolerated in these co-morbidity models.
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